Unique ID issued by UMIN | UMIN000018397 |
---|---|
Receipt number | R000021300 |
Scientific Title | Clinical research on the improving effect of the glucose metabolism and vascular endothelial function by piceatannol |
Date of disclosure of the study information | 2015/07/23 |
Last modified on | 2018/02/02 09:39:51 |
Clinical research on the improving effect of the glucose metabolism and vascular endothelial function by piceatannol
Piceatannol 2
Clinical research on the improving effect of the glucose metabolism and vascular endothelial function by piceatannol
Piceatannol 2
Japan |
Healthy subject and healthy subject with obesity
Endocrinology and Metabolism |
Others
NO
The aim of this study is to clarify whether oral treatment with piceatannol improve glucose/lipid metabolism and vascular endothelial function,or exert the effects of SIRT1 overexpression/activation and anti-fatigue, and also whether difference of the effect of piceatannol exists between healthy subjects and obesity subjects.
Efficacy
* Glucose metabolism: blood glucose, insulin, HbA1c, glycated-albumin
* Endothelial function: FMD, ADMA, high sensitivity-CRP
* Body weight, BMI, amount of body fat, % of body fat, skeletal muscle mass, visceral fat area, (In body)
* Changing of the expression and activity of SIRT1 and AMPK on isolated peripheral blood mononuclear cells
* Lipid metabolism: TC, HDL-C, TG, LDL-C, FFA
* Inflammation: IL-6
* Fatigue: d-ROM, BAP, VAS test (Japan Society of fatigue Science, supervision)
* Metabolites of piceatannol in blood and urine
* Urinary albumin and creatinine
* POMS(Mood profile test, questionnaire method)
* Safety of throughout the entire study period
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
YES
2
Prevention
Other |
Piceatannol(Group)
Taking 4cap/day, twice a day before 30min of breakfast and dinner
Taking piceatannol during 2months
Placebo(Group)
Taking 4cap/day, twice a day before 30min of breakfast and dinner
Taking piceatannol during 2months
20 | years-old | <= |
70 | years-old | > |
Male and Female
(1)Group of Healthy subjects(>=20years old and <70years old): BMI >=18.5 and <25, individuals who have no abnormalities on glucose tolerance, lipid profile and liver function, which are referred by the results of medical examination within one year (When there is no medical examination result within one year, subject needs to take the blood sampling inspection.)
(2)Group of healthy subjects with obesity(>=20years old and <70years old): BMI>=25 or visceral fat area>=100cm2, and individuals who have no medication.
(3)Individual who has the ability of consent and can sign a written informed consent
(1)Women who are pregnant, or possibility of pregnant, or wish to pregnant, or lactating.
(2)Individual who has a smoking habit.
(3)Individual who has a history of allergy to piceatannol
(4)Individual who has a food allergy.
(5)Participants who are considered unsuitable for inclusion by the attending physician.
40
1st name | |
Middle name | |
Last name | Daisuke Koya |
Kanazawa Medical University
Daibetology & Endocrinology
1-1 Daigaku, Uchinada, Kahoku-gun, Ishikawa, 920-0293
076-286-2211
koya0516@kanazawa-med.ac.jp
1st name | |
Middle name | |
Last name | Yuka Kuroshima |
Kanazawa Medical University
Daibetology & Endocrinology
1-1 Daigaku, Uchinada, Kahoku-gun, Ishikawa, 920-0293
076-286-2211
naipicrc@kanazawa-med.ac.jp
Kanazawa Medical University
MORINAGA & CO., LTD.
Profit organization
Japan
NO
金沢医科大学病院/Kanazawa Medical University Hospital.
2015 | Year | 07 | Month | 23 | Day |
Published
Completed
2015 | Year | 05 | Month | 25 | Day |
2015 | Year | 06 | Month | 29 | Day |
2017 | Year | 07 | Month | 31 | Day |
2015 | Year | 07 | Month | 23 | Day |
2018 | Year | 02 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021300
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |